Hypertension, also known as high blood pressure, is one of the most dangerous cardiovascular disorder that is associated with the damage of the arteries, heart, brain, eyes, and other sensitive body parts as asserted by Mike Membrino.

The disease tends to occur when the force of the blood pumping through your arteries is abnormal and too loud. In clinical interventions, hypertension is a challenging condition to manage because the patients are asymptomatic and treatment is preventative rather than palliative.

If the disease is untreated, hypertension has adverse aftermaths, including renal disease, myocardial infarction, and cerebrovascular accident. However, recent research shows that patient receives sufficiently aggressive management with the help of endocannabinoid system.

For example, Michael Membrino argues that the anandamide and CBD hemp extracts are used to lower the blood pressure by triggering the CB1 receptors. In effect, the hypotensive effect is greater in high blood pressure individuals that those with normal blood pressure. This can only suggest that cannabinoids exert stronger effects when a metric is too far from homeostasis. In 1970, the first attempt to use cannabinoids ligands as antihypertensive agents were contemplated and described to provide a long-lasting disease decrease in blood pressure connected with the chronic use of cannabis in human and in response to acute, chronic administration of tetrahydrocannabinol (Cunha et al., 2011).). On the other hand, experiment using rats and mice with regular blood pressure, B1 agonism and antagonism had a little change (Cunha et al., 2011). However, for the hypertensive rats and mice, there was an increase in high blood pressure, suggesting that CB1 receptors only works when blood pressure become deregulated (Cunha et al., 2011).
In the research presented by Mike Membrino President of Neuro-Endoceuticals and a specialist in the field of Adult Neurogenesis, the possible use of cannabinoids as an antihypertensive effect has emerged in demonstrating greater hypotensive efficacy in hypertensive compared to normotensive animals. Besides, the team presented that ECS play a significant role in reducing high blood pressure through the activation of CB1 receptors. In this case, they become upregulated in hypertensive rats, which increases the cardiovascular effects of anandamide.
Hypertension & The Endocannabinoid System
Some of the adverse conditions that may associate with high blood pressure include stroke and heart attacks that occur when there is the restricted flow of blood to the heart, brain, and other parts of the body making the cells not able to absorb enough nutrients for survival. In such cases, ECS tend to regulate ischemia through the effects of CBD that heightens anandamide. The stimulation of anandamide will signals and activate various receptors. Research conducted in 2010 showed that the administered mice with CBD before the induction of coronary ischemia resulted in a dose-dependent reduction in tissue death before reperfusion. The condition was also associated with increased irregular heartbeats.
A Recent study conducted by Pacher, Batkai, and Kunos (2015) indicated that CBD Vape with hemp extracts were found to result in greater and longer lasting decrease of arterial blood pressure in hypertensive individuals as compared to normotensive individuals. Further studies demonstrated that relative modest hypotensive effect of anandamide was present in anesthetized but in no conscious normotensive rats. This shows that CBD effects are associated with high regulation of hypertension. Separately, CBD has indicated to reduce many types of inflammatory and fibrosis biochemical markers as well as oxidative and nitrative stress. Moreover, CBD tend to control and guard human heart cells against the increased free radical damage induced by high glucose exposure.
Hypertension & The Endocannabinoid System
Pacher, P., Bátkai, S., & Kunos, G. (20125). Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology, 48(8), 1130–1138.
Cunha, P., Romão, A. M., Mascarenhas-Melo, F., Teixeira, H. M., & Reis, F. (2011). Endocannabinoid system in cardiovascular disorders – new pharmacotherapeutic opportunities. Journal of Pharmacy and Bioallied Sciences, 3(3), 350–360. http://doi.org/10.4103/0975-7406.84435
Mendizábal, V. E., & Adler-Graschinsky, E. (2007). Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. British Journal of Pharmacology, 151(4), 427–440. http://doi.org/10.1038/sj.bjp.0707261


Leave a Reply

Your email address will not be published. Required fields are marked *